Maze Therapeutics, Inc.

NasdaqGM:MAZE Stock Report

Market Cap: US$1.3b

Maze Therapeutics Future Growth

Future criteria checks 2/6

Maze Therapeutics's earnings are forecast to decline at 10.2% per annum while its annual revenue is expected to grow at 58.4% per year. EPS is expected to decline by 3.9% per annum. Return on equity is forecast to be -61.8% in 3 years.

Key information

-10.2%

Earnings growth rate

-3.88%

EPS growth rate

Pharmaceuticals earnings growth18.9%
Revenue growth rate58.4%
Future return on equity-61.83%
Analyst coverage

Good

Last updated09 Sep 2026

Recent future growth updates

Recent updates

Seeking Alpha • Aug 26

Maze Therapeutics: Intriguing Kidney Disease Assets Put This On The Watchlist

Summary Maze Therapeutics, Inc. has advanced two lead precision medicine programs, MZE782 for PKU and MZE829 for APOL1-mediated kidney disease, with significant clinical progress. MZE782 demonstrated a best-in-class pharmacodynamic profile in Phase 1, supporting a transformative potential for PKU management; Phase 2 is set for mid-2026. MZE829 achieved strong uACR reductions in early Phase 2 data for AMKD, but faces competition from Vertex’s inaxaplin; pivotal trials are planned for 1H 2027. With $494.9m in cash extending into 2029 and a recent $150m licensing deal, MAZE is well-funded but remains pre-revenue, with commercial launches unlikely before 2029. Read the full article on Seeking Alpha
Analysis Article • Dec 15

We're Not Worried About Maze Therapeutics' (NASDAQ:MAZE) Cash Burn

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Mar 26

Maze Therapeutics: Interesting Science But IPO-Related And Other Risks Exist

Summary Maze Therapeutics, a kidney disease therapy developer, recently IPO-ed with a market cap of $487mn and significant early-stage investor backing. Lead asset MZE829 targets APOL1 Kidney Disease, showing promise in preclinical studies and currently in a phase 2 trial. Financials reveal a cash runway of 6.4 quarters from September, with significant R&D and G&A expenses, and a potential price drop post-lockup period. Due to the lack of proof of concept and potential pricing pressures, I recommend avoiding investment in Maze Therapeutics for now. Read the full article on Seeking Alpha

Earnings and Revenue Growth Forecasts

NasdaqGM:MAZE - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20289-253-258-20510
12/31/20279-206-213-17411
12/31/202620-163-157-12911
6/30/202620-134-107-107N/A
3/31/202620-123-122-122N/A
12/31/2025N/A-131-113-112N/A
9/30/2025N/A-101-108-107N/A
6/30/20253-96-107-105N/A
3/31/2025168-266970N/A
12/31/202416837576N/A
9/30/2024168-187778N/A
6/30/2024165-188181N/A
3/31/2024N/A-79-88-87N/A
12/31/2023N/A-100-87-87N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: MAZE is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: MAZE is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: MAZE is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: MAZE's revenue (58.4% per year) is forecast to grow faster than the US market (13.6% per year).

High Growth Revenue: MAZE's revenue (58.4% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: MAZE is forecast to be unprofitable in 3 years.

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/21 17:04
End of Day Share Price 2026/09/18 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Maze Therapeutics, Inc. is covered by 12 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Julian HarrisonBTIG
Debjit ChattopadhyayGuggenheim Securities, LLC
Ananda GhoshH.C. Wainwright & Co.